← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,534	+44	+2%	$196B
2	2 Danaher DHR $158B	2,203	+71	+3%	$147B
3	3 Regeneron Pharmaceuticals REGN $80.1B	1,312	+39	+3%	$89.3B
4	4 Novartis NVS $279B	1,255	-17	-1%	$13.6B
5	5 Agilent Technologies A $49.1B	1,015	+10	+1%	$37.9B
6	6 Illumina ILMN $41B	796	-15	-2%	$19.7B
7	7 Charles River Laboratories CRL $14.4B	676	+42	+7%	$14.1B
8	8 Revvity RVTY $17B	526	+37	+8%	$11B
9	9 Alnylam Pharmaceuticals ALNY $30B	499	0	0%	$17.2B
10	10 CRISPR Therapeutics CRSP $4.86B	483	+13	+3%	$4.1B
11	11 DELISTED CATALENT, INC. CTLT	442	+18	+4%	$10.5B
12	12 Sarepta Therapeutics SRPT $1.78B	415	+19	+5%	$10.8B
13	13 Bruker BRKR $8.47B	388	+28	+8%	$10.4B
14	14 Ionis Pharmaceuticals IONS $7.1B	362	-1	-0.3%	$6.17B
15	15 Ginkgo Bioworks DNA $776M	342	0	0%	$1.51B
16	16 Azenta AZTA $1.63B	329	+10	+3%	$3.43B
17	17 10x Genomics TXG $9.52B	290	+15	+5%	$3.89B
18	18 ARK Genomic Revolution ETF ARKG $2.05B	286	-14	-5%	$609M
19	19 Intellia Therapeutics NTLA $1.6B	285	-8	-3%	$2.51B
20	20 Qiagen QGEN $9.41B	283	+5	+2%	$5.83B
21	21 Arrowhead Research ARWR $8.25B	274	+8	+3%	$2.76B
22	22 Ultragenyx Pharmaceutical RARE $1.47B	270	+33	+14%	$3.73B
23	23 Pacific Biosciences PACB $619M	268	-6	-2%	$1.01B
24	24 Guardant Health GH $21.9B	258	-37	-13%	$2.3B
25	25 Vericel Corp VCEL $2.06B	256	+29	+13%	$2.68B